Genomed Spólka Akcyjna Valuation

Q: What is the Fair Price of GEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

GEN (PLN27) is trading below our estimate of [[fair value]] (PLN68.38)

Is GEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GEN (PLN27) is trading below our estimate of fair value (PLN68.38)

Significantly Below Fair Value: GEN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GEN?

Key metric: As GEN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GEN. This is calculated by dividing GEN's market cap by their current earnings.
What is GEN's PE Ratio?
PE Ratio	60.6x
Earnings	zł588.67k
Market Cap	zł35.68m

GEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	21.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does GEN's PE Ratio compare to its peers?

The above table shows the PE ratio for GEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.1x
MAB Mabion	18.8x	-116.7%	zł192.0m
SVE Synthaverse	69.1x	n/a	zł307.1m
BGD Biogened	11.6x	n/a	zł56.5m
EGRX Eagle Pharmaceuticals	1x	n/a	US$8.5m
GEN Genomed Spólka Akcyjna	60.6x	n/a	zł35.7m

Price-To-Earnings vs Peers: GEN is expensive based on its Price-To-Earnings Ratio (60.6x) compared to the peer average (38.7x).

Price to Earnings Ratio vs Industry

How does GEN's PE Ratio compare vs other companies in the European Biotechs Industry?

5 Companies	Price / Earnings	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: GEN is expensive based on its Price-To-Earnings Ratio (60.6x) compared to the European Biotechs industry average (27.3x).

Price to Earnings Ratio vs Fair Ratio

What is GEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GEN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	60.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GEN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.